摘要
心血管疾病已成为糖尿病患者死亡的首要原因,单纯血糖控制对降低心血管死亡风险的作用有限。卡格列净(canagliflozin)是一种钠葡萄糖共转运蛋白(SGLT)2抑制剂,通过阻断肾脏对葡萄糖的重吸收来降低血糖水平,不依赖于胰岛素的分泌或作用,具有降糖、减重、降压等作用,还能够显著降低心血管事件风险,本文主要就卡格列净的心血管保护作用进行综述。
Cardiovascular diseases have become the leading cause of death in patients with diabetes mellitus(DM).Blood glucose control alone plays a limited role in reducing the risk of cardiovascular death.Canagliflozin is a sodium glucose co-transporter 2(SGLT2) inhibitor.It can reduce blood glucose level by blocking renal reabsorption of glucose independent from insulin secretion or effect.Canagliflozin can lower blood glucose,reduce body weight and blood pressure etc.,and significantly reduce the risk of cardiovascular events.The present article mainly makes a review on cardiovascular protective effect of canagliflozin.
作者
褚文欣
梁梅花
CHU Wen-xin;LIANG Mei-hua(Department of Endocrinology and Metabolism,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)
出处
《心血管康复医学杂志》
CAS
2023年第4期422-426,共5页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心血管疾病
糖尿病
2型
钠-葡萄糖转运体2
Cardiovascular diseases
Diabetes mellitus,type 2
Sodium-glucose transporter 2
